| Literature DB >> 11429667 |
Abstract
The roles of tumour necrosis factor (TNF) and anti-TNF therapy in malignancy are reviewed, including an overview of baseline risk factors for malignancy in inflammatory diseases and the incidences of malignancies observed in clinical trials of an anti-TNF-a therapy, infliximab. The preclinical data and early clinical experience presented for infliximab do not provide evidence for a causal relationship between TNF-a antagonism and the development of lymphoid or nonlymphoid cancers.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11429667 DOI： 10.1155/2001/403102
Source DB: PubMed Journal: Can J Gastroenterol ISSN： 0835-7900 Impact factor: 3.522